Business Wire

CA-LIVERAMP

15.6.2021 15:32:12 CEST | Business Wire | Press release

Share
LiveRamp and Carrefour Partner to Deliver Next-Generation Retail Offerings

LiveRamp ® (NYSE: RAMP) today announced an expanded global partnership with Carrefour (OTCMKTS: CRERF) to enable robust data collaboration, analytics and innovation capabilities through LiveRamp’s Safe Haven . Using LiveRamp’s best-in-class privacy-preserving technologies, retailers, consumer packaged goods (CPGs) brands and Carrefour partners can execute safe, simple and productive data collaboration on an unprecedented global scale. Safe Haven is currently available in the U.S., UK, France, China, Japan and Australia, and, with Carrefour, is expanding to Spain, Italy, Belgium, Poland, Romania, Argentina, Brazil and Taiwan. LiveRamp’s Safe Haven is part of a new business unit that Carrefour is launching on this occasion: “Carrefour Links .” The partnership was announced at a press conference in Paris today.

“LiveRamp will be a critical accelerator of Carrefour’s transformation into an industry-leading data-driven retailer,” said Elodie Perthuisot, Executive Director E-Commerce, Data and Digital Transformation Carrefour Group. “We are delivering great value by working more collaboratively with our CPG and retail supply partners with Carrefour Links. We are excited by our partnership with LiveRamp, working together to deliver robust new consumer insights and capabilities to hundreds of our CPG partners on a global scale.”

By delivering data connectivity and identity management in a neutral, secure and permissioned environment, LiveRamp makes a breadth of new use cases and revenue streams possible for retailers while transforming the way they work with their supply partners. Through Carrefour Links, Safe Haven enables Carrefour to partner more closely with its CPG partners across nine international markets to deliver enhanced data collaboration capabilities including:

  • Deeper Insights and Analytics 一Packaged reports provide robust insights into campaign performance, category management, and shopper analytics. Safe Haven also offers the ability for data science teams to utilize their own models and machine learning.
  • Omnichannel Activation 一Activate CPG campaigns using Carrefour data across social and open web platforms and Carrefour owned-and-operated assets.
  • Better Measurement 一CPGs can better understand the impact of marketing activities on sales utilizing retail data and move the needle to drive key business outcomes.

“Data is transforming the customer experience globally – and Carrefour is at the very forefront of this trend with its Carrefour Links platform,” said Warren Jenson, president of LiveRamp. “With LiveRamp Safe Haven, brands and their partners can now safely collaborate to deliver better customer experiences and drive business outcomes. We are proud to enable this groundbreaking capability for Carrefour across its CPG partner network and in over nine countries.”

LiveRamp’s expanded partnership with Carrefour signals the growing momentum of Safe Haven, which now serves more than 45 customers across retail, grocery, CPG, consumer electronics and other verticals. LiveRamp’s recent acquisition of DataFleets brings industry-leading privacy-enhancing technologies to Safe Haven, allowing customers to implement configurable data controls. LiveRamp’s Safe Haven makes data collaboration safe and easy for customers regardless of the technical infrastructure or cloud platform used by each party, without moving data.

“Safe Haven is enabling clients to collaborate across clouds, partners and borders to drive innovation, deliver better customer experiences and achieve competitive advantage,” continued Jenson. “In just over a year since announcing Safe Haven, we’ve gained 30% market share within U.S. grocery and big box retail, and in Europe are trailblazing the way with Carrefour and other leading retailers. As we continue to expand our international footprint, we are excited to now serve more than 30% of the 50 largest global CPGs.”

Visit the LiveRamp website to find more information on Safe Haven and Safe Haven for Retail .

About Carrefour Group
With a multi-format network of some 13 000 stores in more than 30 countries, the Carrefour Group is one of the world's leading food retailers. Carrefour recorded gross sales of €78.6 billion in 2020. It has more than 320,000 employees who help to make Carrefour the world leader in the food transition for everyone, providing everybody with access to high-quality, affordable food every day, in all locations.

For more information, visit www.carrefour.com , or find us on Twitter (@GroupeCarrefour) and LinkedIn (Carrefour).

About LiveRamp
LiveRamp is the leading data connectivity platform for the safe and effective use of data. Powered by core identity resolution capabilities and an unparalleled network, LiveRamp enables companies and their partners to better connect, control, and activate data to transform customer experiences and generate more valuable business outcomes. LiveRamp’s fully interoperable and neutral infrastructure delivers end-to-end addressability for the world’s top brands, agencies, and publishers. For more information, visit www.LiveRamp.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye